Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02125721 · ClinicalTrials.gov registry record · Phase 4

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

A Phase 4 study, sponsored by NYU Langone Health.

Completed
Registry status
Phase 4
Development phase
10
Enrollment target

NCT02125721: Completed Phase 4 study, sponsored by NYU Langone Health.

NCT02125721 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02125721, a Phase 4 study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Phase 4
Development phase
10 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Primary Outcome

We will test for a negative correlation between progressive increases in doses of thiol drugs and cystine capacity

Interventions

  • DRUG Tiopronin 1g per day
  • DRUG Tiopronin 2g per day
  • DRUG Tiopronin 3g per day

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2012-06
Est. Completion 2017-12
Phase Phase 4
NYU Langone Health

1,164 total trials

What the finished NCT02125721 record still lists

NCT02125721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 3 interventions - of which Tiopronin 1g per day is the first listed.

NCT02125721 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02125721 about?

NCT02125721 is a clinical study titled "Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria". The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help gui...

What is the current status of trial NCT02125721?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2012-06. Estimated completion is 2017-12.

What interventions are being tested in trial NCT02125721?

The interventions under investigation include: Tiopronin 1g per day (DRUG), Tiopronin 2g per day (DRUG), Tiopronin 3g per day (DRUG).

Who is sponsoring clinical trial NCT02125721?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02125721's enrollment target sits among peer trials

10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02125721, the US trial registry maintained by the National Library of Medicine. NCT02125721 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.